The Medicines Company
Closed portfolio with a later-stage archive tilt
According to ClinicalTrials.gov-derived indexes, The Medicines Company sits in the top decile of US sponsors by registered trial count (#473 of 15,742 sponsors by registered trial count).
The Medicines Company: 35 sponsored US clinical trials, none currently recruiting.
The Medicines Company sponsors 35 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 32 completed. 24 of these trials are in Phase 3-4 (later-stage) and 11 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Thrombosis, with 2 trials.
Top-decile sponsor footprint
The Medicines Company ranks in the top decile of sponsors by registered trial count (#473 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
32 of 35 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.4%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
35 total, page 1 of 1
Inclisiran for Participants With Atherosclerotic Cardiovascular Disease and Elevated Low-density Lipoprotein Cholesterol
NCT03399370
Trial to Evaluate the Effect of Inclisiran Treatment on Low Density Lipoprotein Cholesterol (LDL-C) in Subjects With Heterozygous Familial Hypercholesterolemia (HeFH)
NCT03397121
Safety of Either a Single or Two Intravenous Doses of Orbactiv in Participants With Acute Bacterial Skin and Skin Structure Infection
NCT02925416
A Study of ALN-PCSSC in Participants With Homozygous Familial Hypercholesterolemia (HoFH)
NCT02963311
Trial to Evaluate the Effect of ALN-PCSSC Treatment on Low Density Lipoprotein Cholesterol (LDL-C)
NCT02597127
A Study to Evaluate the Safety of a Single Intravenous (IV) Dose of Orbactiv (Oritavancin) in Participants on Chronic Warfarin Therapy Being Treated For Acute Bacterial Skin and Skin Structure Infection (ABSSSI)
NCT02452918
Study to Evaluate the Safety, Tolerability and Pharmacokinetics of a New Formulation of Oritavancin in Healthy Volunteers
NCT02471690
Safety and Clinical Utility Study of SSEC Fentanyl 40 mcg for Acute Post-op Pain Management in Pediatric Participants
NCT02395653
Cangrelor to Clopidogrel or Prasugrel Transition Study
NCT01979445
ENDOvascular Interventions With AngioMAX: The ENDOMAX Trial
NCT01913483
Cangrelor Prasugrel Transition Study
NCT01852019
Cangrelor Ticagrelor Transition Study
NCT01766466
A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention (PCI) (CHAMPION PHOENIX)
NCT01156571
Clevidipine in the Treatment of Blood Pressure in Patients With Acute Heart Failure (PRONTO)
NCT00803634
Clevidipine Bolus Administration in the Treatment of Hypertensive Patients Undergoing Cardiac Surgery (SPRINT)
NCT00799604
Maintenance of Platelet Inhibition With Cangrelor
NCT00767507
Clevidipine in the Treatment of Patients With Acute Hypertension and Intracerebral Hemorrhage (ACCELERATE)
NCT00666328
Assess the Effect of Cangrelor at the Therapeutic Dose and a Supratherapeutic Dose Level on the QT/QTc Interval in Healthy Volunteers
NCT00699504
Clevidipine in the Treatment of Patients With Severe Hypertension (VELOCITY)
NCT00369837
Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition.
NCT00385138
A Clinical Trial to Demonstrate the Efficacy of Cangrelor
NCT00305162
Pharmacokinetics/Pharmacodynamics (PK/PD) of Cangrelor
NCT00102674
Clevidipine in the Perioperative Treatment of Hypertension (ECLISPE-SNP)
NCT00093912
Clevidipine in the Postoperative Treatment of Hypertension (ECLIPSE-NIC)
NCT00093925
Angiomax in Patients With HIT/HITTS Type II Undergoing CPB
NCT00079508
Bivalirudin in Patients With Acute Myocardial Infarction (AMI) Undergoing Primary PCI
NCT00093184
Comparing Angiomax to Heparin With Protamine in Patients Undergoing Cardiopulmonary Bypass (CPB)
NCT00079586
Clevidipine in the Perioperative Treatment of Hypertension (ECLIPSE-NTG)
NCT00093886
Study of Clevidipine Assessing Its Preoperative Antihypertensive Effect in Cardiac Surgery (ESCAPE-1)
NCT00093249
Study of Clevidipine Assessing Its Postoperative Antihypertensive Effect in Cardiac Surgery (ESCAPE-2)
NCT00093262
Angiomax in Patients With HIT/HITTS Type II Undergoing Off-Pump Coronary Artery Bypass Grafting (CABG) (CHOOSE)
NCT00073580
Comparing Angiomax to Heparin With Protamine Reversal in Patients OPCAB
NCT00073593
Comparison of Angiomax Versus Heparin in Acute Coronary Syndromes (ACS)
NCT00093158
Study Of Angiomax In Infants Under Six Months With Thrombosis
NCT00043277
Anticoagulant Therapy With Bivalirudin in the Performance of Percutaneous Coronary Intervention in Patients With Heparin-Induced Thrombocytopenia (AT BAT, First Inning)
NCT00043940
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 8 |
| Phase 3 | 22 |
| Phase 4 | 2 |
Therapeutic Areas
How the The Medicines Company archive is shaped
35 indexed studies, none listed as recruiting (0% open); 32 completed (91%).
Phase mix: 24 late (III/IV) vs 11 early (I/II) (later-stage heavy).
Top condition: Thrombosis (2 trials), 5 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
The Medicines Company: archived-pipeline peers nationwide
Peers matched on 35 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
The Medicines Company sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 35 archived trials
- ACADIA Pharmaceuticals · 35 trials · 9% recruiting
- INSYS Therapeutics · 35 trials · 0% recruiting
- Merz North America · 35 trials · 3% recruiting
- Palo Alto Veterans Institute for Research · 35 trials · 20% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this The Medicines Company page
35 registered trials is a research-attention snapshot, not an endorsement of The Medicines Company or any single study.
- None of The Medicines Company's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Thrombosis is the condition The Medicines Company studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Thrombosis trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
The Medicines Company pipeline card: 35 registered trials from official public datasets.Report a data error.